Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dolutegravir + tenofovir disoproxil fumarate + lamivudine
- Development stage
- Phase 4
- Lead developer
- ViiV Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dolutegravir + tenofovir disoproxil fumarate + lamivudine is a fixed-dose combination antiretroviral medication used as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 35–40 kg. The combination consists of three agents with distinct mechanisms: dolutegravir, an integrase strand transfer inhibitor (INSTI), blocks HIV integrase and prevents integration of viral DNA into the host genome; both tenofovir disoproxil fumarate and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit reverse transcriptase, leading to chain termination during viral DNA synthesis. This regimen is recommended by the World Health Organization as first-line therapy for HIV/AIDS in adults. It is administered orally once daily as a single tablet[1][2][5].
- Brand names
- AcriptegaDamicavaDovimilEmdoltenKocitafKovatraxLanogravLavernLuvigenMilutinMyteladovNuvacoOdystraRanegaReydinTeladoTelatriTemivTladeezViripilVolutripVonavir
- Other names
- tenofovir/lamivudine/dolutegravir
02
Targets
Integrase allosteric pocket (HIV)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on dolutegravir + tenofovir disoproxil fumarate + lamivudine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dolutegravir + tenofovir disoproxil fumarate + lamivudine.